ArticleThe Journal of dermatology2024

Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.

Akio Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.